Copyright
©The Author(s) 2020.
World J Diabetes. Dec 15, 2020; 11(12): 596-610
Published online Dec 15, 2020. doi: 10.4239/wjd.v11.i12.596
Published online Dec 15, 2020. doi: 10.4239/wjd.v11.i12.596
Figure 3 Podocyte foot processes.
A: Non-diabetic db/+ mice; B: Vehicle-treated db/db diabetic mice demonstrate effacement of podocyte foot processes(FPs); C: Empagliflozin restores the structure of FPs in db/db mice. Transmission electron microscopy: ×100000.
- Citation: Klimontov VV, Korbut AI, Taskaeva IS, Bgatova NP, Dashkin MV, Orlov NB, Khotskina AS, Zavyalov EL, Klein T. Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice. World J Diabetes 2020; 11(12): 596-610
- URL: https://www.wjgnet.com/1948-9358/full/v11/i12/596.htm
- DOI: https://dx.doi.org/10.4239/wjd.v11.i12.596